MyFinsight
Home
Compare
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Net Income
-$4,017,000
EPS
-$3.4
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
Revenue
-
-
0*
Cost of revenues
-
-
0*
Gross profit
-
-
0*
Gain on lease termination
-
-
0*
Research and development
2,792,000
1,915,000
1,039,000*
General and administrative
1,312,000
1,631,000
1,290,750*
Impairment of goodwill
-
2,044,000
-
Total operating expenses
4,104,000
5,590,000
2,329,750*
Loss from operations
-4,104,000
-5,590,000
-2,329,750*
Change in fair value of convertible notes
-
-
0*
Change in fair value to bridge notes derivative liability
-
-
0*
Change in fair value of contingent consideration
-
-
0*
Forward Sales Contract Expense
-
-
-1,470,500*
Change in fair value of warrant liabilities
-
-
-250*
Interest income
-
-
20,750*
Interest income (expense), net
55,000
44,000
-6,750*
Gain on extinguishment of contingent liability
41,000
-
200,000*
Other expense, net
-1,000
-
53,750*
Total other income (expense), net
95,000
44,000
-1,202,500*
Loss before income taxes
-4,009,000
-5,546,000
-3,532,250*
Benefit (provision) for income taxes
-
-40,000
-11,250*
Net loss
-4,009,000
-5,506,000
-3,521,000*
Series a preferred stock dividend
8,000
-
4,000*
Net loss attributable to common stockholders
-4,017,000
-
-3,525,000
Basic EPS
-3.4
-6.95
-0.559
Diluted EPS
-3.4
-6.95
-0.559
Basic Average Shares
1,183,000
792,000
6,307,000
Diluted Average Shares
1,183,000
792,000
6,307,000
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
attributable to common...
-$4,017,000
Net loss
-$4,009,000
Series a preferred
stock dividend
$8,000
Interest income
(expense), net
$55,000
Gain on
extinguishment of contingent...
$41,000
Loss before income
taxes
-$4,009,000
Total other income
(expense), net
$95,000
Other expense, net
-$1,000
Loss from operations
-$4,104,000
Total operating
expenses
$4,104,000
Research and development
$2,792,000
General and
administrative
$1,312,000
Buy us a coffee
Ernexa Therapeutics Inc. (ERNAW)
Ernexa Therapeutics Inc. (ERNAW)